Abstract
Serum ferritin level, the most commonly used marker for determining iron status in patients with chronic kidney disease, is influenced by factors such as inflammation and malnutrition. Moreover, there seems to be considerable biological variability and analytical variation between different serum ferritin assays. This Practice Point commentary discusses a recent paper by Ford et al. that examined the interassay differences and short-term intraindividual variability of serum ferritin measurements in patients on chronic hemodialysis. A comparison of six commonly used serum ferritin immunoassays revealed intermethod variation of up to 337 pmol/l among hemodialysis and nonhemodialysis patients. The intraindividual coefficients of variation for serum ferritin level in 60 stable hemodialysis patients ranged from 2% to 62% over an initial 2-week period and from 3% to 52% over a 6-week period. This commentary discusses Ford et al.'s paper and supports the conclusion that nephrologists should not use a single serum ferritin value to guide intravenous iron treatment in patients on chronic hemodialysis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kalantar-Zadeh K et al. (2004) Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 19: 141–149
Pilon VA et al. (1981) Day-to-day variation in serum ferritin concentration in healthy subjects. Clin Chem 27: 78–82
Fishbane S et al. (2001) A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 60: 2406–2411
Ford BA et al. (2008) Variability of ferritin measurements in chronic kidney disease; implications for iron management. Kidney Int [10.1038/ki.2008.526]
KDOQI (2006) KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47 (Suppl 3): S11–S145
Tarng DC et al. (1999) Erythropoietin hyporesponsiveness: from iron deficiency to iron overload. Kidney Int 55 (Suppl 69): S107−S118
Coyne DW et al. (2007) Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 18: 975–984
Kuo KL et al. (2008) Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients. J Am Soc Nephrol 19: 1817–1826
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Tarng, DC. The conundrum of serum ferritin measurement in patients with chronic kidney disease. Nat Rev Nephrol 5, 66–67 (2009). https://doi.org/10.1038/ncpneph1018
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpneph1018
This article is cited by
-
Plasma neutrophil gelatinase-associated lipocalin is associated with iron status in anemic patients with pre-dialysis chronic kidney disease
Clinical and Experimental Nephrology (2018)
-
ESA and iron therapy in chronic kidney disease: a balance between patient safety and hemoglobin target
Kidney International (2014)